CAR-T cells therapy: a potential new strategy against prostate cancer

Abstract

There have already been some therapies for cancer, but further research is still in urgent need to effectively treat prostate cancer. Chimeric antigen receptor T (CAR-T) cells therapy is a popular new therapy to treat tumor, although it is mostly in the clinical research stage except for a few specific applications. Prostate cancer is a type of malignancy tumor in man occurring frequently. It has the second highest incidence in man and the fifth highest fatality rate worldwide. At present, the main treatment for prostate cancer includes reduce the androgen concentration of patients through drugs, operation to remove prostate tumor, pelvic radio therapy and chemotherapy. On how CAR-T works to treat prostate cancer, more study is currently being done. This review introduces the structure and the feasibility of CAR-T as a means of treating prostate cancer due to the research of three antigens which have prostate specific (prostate specific membrane antigen, prostate stem cell antigen and epithelial cell adhesion molecule) and discusses their application in prostate cancer.